EZZ Life Science Holdings Ltd - Asset Resilience Ratio

Latest as of June 2025: 2.63%

EZZ Life Science Holdings Ltd (EZZ) has an Asset Resilience Ratio of 2.63% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EZZ Life Science Holdings Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$891.50K
≈ $630.79K USD Cash + Short-term Investments

Total Assets

AU$33.96 Million
≈ $24.03 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2023–2024)

This chart shows how EZZ Life Science Holdings Ltd's Asset Resilience Ratio has changed over time. See EZZ equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down EZZ Life Science Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EZZ Life Science Holdings Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$891.50K 2.63%
Total Liquid Assets AU$891.50K 2.63%

Asset Resilience Insights

  • Limited Liquidity: EZZ Life Science Holdings Ltd maintains only 2.63% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

EZZ Life Science Holdings Ltd Industry Peers by Asset Resilience Ratio

Compare EZZ Life Science Holdings Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for EZZ Life Science Holdings Ltd (2023–2024)

The table below shows the annual Asset Resilience Ratio data for EZZ Life Science Holdings Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.63% AU$891.50K
≈ $630.79K
AU$33.96 Million
≈ $24.03 Million
+0.45pp
2023-12-31 2.18% AU$556.49K
≈ $393.75K
AU$25.55 Million
≈ $18.08 Million
--
pp = percentage points

About EZZ Life Science Holdings Ltd

AU:EZZ Australia Biotechnology
Market Cap
$16.98 Million
AU$23.99 Million AUD
Market Cap Rank
#25636 Global
#1126 in Australia
Share Price
AU$0.51
Change (1 day)
+0.99%
52-Week Range
AU$0.51 - AU$3.32
All Time High
AU$4.93
About

EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consum… Read more